Clinical Nanomaterials: A Safe‐by‐Design Strategy towards Safer Nanomaterials in Nanomedicines (Adv. Mater. 45/2019)

Liang Yan,Feng Zhao,Jing Wang,Yan Zu,Zhanjun Gu,Yuliang Zhao
DOI: https://doi.org/10.1002/adma.201970325
IF: 29.4
2019-01-01
Advanced Materials
Abstract:In article number 1805391, Zhanjun Gu, Yuliang Zhao, and co-workers review clinical potential and toxicological mechanisms of the most important nanomaterials, including liposomes, polymeric and biomacromolecular nanomaterials, inorganic nanomaterials, and carbon-based nanomaterials with a view to avoiding potential adverse effects of emerging nanomedicines. Based on the available information, an overview of the principles in developing “safe-by-design” nanomaterials for medical applications is given.
What problem does this paper attempt to address?